Apr 11: Granted orphan drug status in the EU for treatment of fragile X syndrome [2]. 28/11/2011 14:19:45
Trial or other data
May 11: Randomised, double-blind, placebo-controlled Phase 3 study initiated, to evaluate the effects of arbaclofen on social impairment in adolescents and adults (ages 12 to 25) with fragile X syndrome. A second study in children (ages 5 to 11) is expected to begin in early summer 2011. [1] 03/06/2011 14:33:45
References
Available only to registered users
Category
BNF Category:
Awaiting Update (99)
Pharmacology:
oral selective gamma-amino butyric acid type B (GABA-B) receptor agonist
Uk Medicines Information 